Latest / Deborah Kobylt LIVE / Deborah Kobylt LIVE_ Dr. Robert Winters
Transcript
- 0:02Speaker 1: And now welcome Deborah Kolbaut. Thanks so much, Kirk, for
- 0:06Speaker 1: that introduction. And thanks everybody for joining us for Deborah
- 0:09Speaker 1: Kolbaut Live. On the phone with us, we've got Dr.
- 0:11Speaker 1: Robert Winters, infectious disease specialist over at Providence St. John
- 0:16Speaker 1: and UCLA Santa Monica. Thank you very much, doctor, for
- 0:19Speaker 1: joining us.
- 0:21Speaker 2: Hey, good afternoon.
- 0:23Speaker 1: Yeah, thank you. So why don't you give us some
- 0:26Speaker 1: of the latest of what is going on? What is
- 0:28Speaker 1: the scene there of what's going on over at both
- 0:31Speaker 1: at Providence St. John and also at UCLA. Have you
- 0:34Speaker 1: been overwhelmed there with COVID patients or are you able
- 0:38Speaker 1: to handle the amount of patients coming into those hospitals?
- 0:43Speaker 2: Right. Well, I'm not a spokesman for either hospital, but
- 0:45Speaker 2: I can tell you as I've been at both facilities,
- 0:49Speaker 2: they are managing a fair number of COVID-19 patients. The
- 0:55Speaker 2: ICUs are full, but there's regular patients in there that
- 0:58Speaker 2: are not COVID patients because obviously life goes on with
- 1:03Speaker 2: heart attacks and strokes and other problems. But I think
- 1:05Speaker 2: we're doing a very good job managing the current patient flow.
- 1:11Speaker 1: You talked a little bit briefly earlier to me about
- 1:15Speaker 1: viral load. Can you explain to me what is viral
- 1:19Speaker 1: load and to everyone else out there? And it has
- 1:20Speaker 1: to do with when one is just infected with the coronavirus, right?
- 1:27Speaker 2: Right. Viral load. allows doctors and scientists to talk about
- 1:32Speaker 2: actually how much virus is present. So individual viral particles,
- 1:37Speaker 2: we call them virions. And we can determine how much virus,
- 1:43Speaker 2: assign a number to it, how much virus is present
- 1:45Speaker 2: in any one individual per unit of tissue that we're
- 1:49Speaker 2: looking at. And so what we've learned about coronavirus is
- 1:52Speaker 2: that The initial infection, the first few days where people
- 2:00Speaker 2: become symptomatic, they have extremely high viral loads. The immune
- 2:05Speaker 2: system has not recognized the virus, has never seen it before.
- 2:09Speaker 2: So the viral reproduction essentially goes unchecked. And then we
- 2:13Speaker 2: can watch the normal evolution where that viral load number
- 2:17Speaker 2: reaches a very high level in the first few days,
- 2:20Speaker 2: maybe the first week after initial appearance of the illness.
- 2:25Speaker 2: And then it begins to go down as the immune
- 2:27Speaker 2: system recognizes this virus. You start forming antibody. And then typically,
- 2:34Speaker 2: as you start developing antibody levels that are high enough
- 2:37Speaker 2: to attack the virus, the viral load essentially goes away,
- 2:42Speaker 2: goes down to zero as the antibody levels come up.
- 2:45Speaker 2: And that's a normal type of infection where people get infected,
- 2:49Speaker 2: they're ill, and then they get better. But what happens
- 2:53Speaker 2: in people that ultimately die from this infection, their viral
- 2:57Speaker 2: loads do not go down, but they remain elevated and
- 3:01Speaker 2: they tend to go even higher. That obviously represents a
- 3:05Speaker 2: bigger problem because the higher the viral load, the more
- 3:09Speaker 2: virus that's present, it becomes a more complicated infection. And obviously,
- 3:15Speaker 2: as there's more virus present, it starts becoming what we
- 3:19Speaker 2: call a lower respiratory infection. And as you get the
- 3:22Speaker 2: lower part of your lungs involved, what we call pneumonia,
- 3:25Speaker 2: that starts triggering this very, very severe inflammatory response. And
- 3:30Speaker 2: then ultimately, people who don't survive this infection, it's not
- 3:34Speaker 2: that they actually die from the virus. They die from
- 3:36Speaker 2: the inflammatory response that this virus creates, and they die
- 3:40Speaker 2: from what's called adult respiratory distress syndrome, or ARDS for short.
- 3:45Speaker 1: What do you do if you're a person who has inflammation,
- 3:49Speaker 1: who has asthma? I mean, that's kind of a scary thing.
- 3:52Speaker 1: I mean, people that I know who have these issues
- 3:56Speaker 1: are staying clear of most people and taking this very seriously,
- 4:01Speaker 1: but it's still hard to do. You've got to go
- 4:02Speaker 1: get your groceries. You live in a community or a
- 4:05Speaker 1: home with people that may or may not still be
- 4:07Speaker 1: coming in and out. Are they very susceptible? Not necessarily
- 4:11Speaker 1: if they're older, but if they have those conditions.
- 4:15Speaker 2: Well, clearly we know there are risk groups for people
- 4:18Speaker 2: that may have more severe disease or be at higher
- 4:21Speaker 2: risk for dying from it. And clearly those individuals with
- 4:25Speaker 2: underlying cardiovascular problems, diabetes mellitus, chronic lung disease, including asthma,
- 4:33Speaker 2: and interestingly, a history of hypertension and recent diagnosis of cancer,
- 4:39Speaker 2: those individuals tend also to have a more complicated type
- 4:42Speaker 2: of illness. So it's older age plus underlying medical conditions
- 4:47Speaker 2: like I just described.
- 4:49Speaker 1: How are we doing in the hospitals? Do we have
- 4:52Speaker 1: enough ventilators? The projection and the numbers that we've seen
- 4:56Speaker 1: from the governor's office, for example, do you expect that
- 5:01Speaker 1: it's going to reach that level? Or will we be
- 5:04Speaker 1: able to taper it off based on how we are
- 5:07Speaker 1: all behaving in our community?
- 5:10Speaker 2: You know, I think it really depends where you are
- 5:12Speaker 2: in this country, if not throughout the world. I mean,
- 5:15Speaker 2: I think New York and New Jersey, I think, are
- 5:19Speaker 2: going to be far more pressured than at least my
- 5:22Speaker 2: experience here in Santa Monica. I think there are other
- 5:27Speaker 2: places that we are clearly concerned about, whether it's going
- 5:30Speaker 2: to be Michigan and Chicago. But it really, I think,
- 5:34Speaker 2: depends on where you are. And it's not a one-size-fits-all
- 5:39Speaker 2: type of answer. As I told you at the beginning,
- 5:42Speaker 2: I think we're managing this problem very well at the
- 5:46Speaker 2: present time. But as you know, we spoke a couple
- 5:49Speaker 2: weeks ago, and our concern back then was do we
- 5:53Speaker 2: have the capacity to treat the large number of patients
- 5:59Speaker 2: that were expected to present to hospital emergency rooms with
- 6:03Speaker 2: this very severe infection. And I think that that concern
- 6:07Speaker 2: that was discussed a month ago or so is really
- 6:11Speaker 2: coming to become true.
- 6:16Speaker 1: Well, now that we have the overflow, right, we've got
- 6:19Speaker 1: the ship down, I believe, in Long Beach. And that
- 6:23Speaker 1: what takes other patients, not COVID patients I'm hearing, but
- 6:27Speaker 1: other patients, right, with other issues?
- 6:30Speaker 2: Yeah, the strategy was to get non-COVID patients out of
- 6:34Speaker 2: the hospitals, get them on the ship, So then the
- 6:37Speaker 2: hospitals can be dedicated to taking care of corona patients.
- 6:40Speaker 2: You know, it's very time consuming taking care of these
- 6:42Speaker 2: patients because health care workers, you know, we don't want
- 6:45Speaker 2: to get exposed. We don't want to get infected. So
- 6:48Speaker 2: it's a very labor intensive type of treatment. So it's
- 6:51Speaker 2: hard to put on all the equipment, the gown, the gloves,
- 6:56Speaker 2: the eye protection, the mask. You take care of a
- 6:59Speaker 2: patient for 20 or 30 minutes. Then you have to
- 7:01Speaker 2: take all that off and clean yourself up, and now
- 7:04Speaker 2: there's a patient that doesn't have that illness. They're dealing with, say,
- 7:09Speaker 2: a bad heart attack. And then now you can deal
- 7:12Speaker 2: with them, but then you've got to get back to
- 7:14Speaker 2: the other patient and re-gown and re-dress again. So it's
- 7:16Speaker 2: probably better to have what we call cleaner patients, meaning
- 7:20Speaker 2: non-COVID-19-infected patients, have them out of the hospital. And I
- 7:25Speaker 2: think that what the USS Mercy made a lot of
- 7:30Speaker 2: sense to me get non-COVID patients out of the hospitals
- 7:34Speaker 2: and let the hospitals take care of this more active infection.
- 7:40Speaker 1: Where you're located now, do you have enough supplies? Do
- 7:43Speaker 1: you have enough ventilators? Should you get an onslaught of
- 7:46Speaker 1: patients with COVID-19? And also, do you have supplies enough
- 7:50Speaker 1: masks and gloves and everything that you need for doctors
- 7:55Speaker 1: and nurses?
- 7:57Speaker 2: Right. Well, again, as I told you, I don't speak
- 7:58Speaker 2: for either institution, but I do not see a shortage.
- 8:01Speaker 2: But again, I think we may be early in this
- 8:06Speaker 2: pandemic locally where I am. I see no shortage of
- 8:11Speaker 2: masks and gloves and gowns. There seems to be ample supply.
- 8:15Speaker 2: But again, the concern isn't today and tomorrow. It's really
- 8:19Speaker 2: where are we going to be two or even three
- 8:22Speaker 2: weeks from now? Because Some of the projections, which I'm
- 8:25Speaker 2: sure you're familiar with, where we're talking 100,000 up to 240,000 deaths.
- 8:32Speaker 2: I mean, there's a lot of other folks that are
- 8:35Speaker 2: going to need to be taken care of that don't die,
- 8:38Speaker 2: but they're still in the hospital. So it's not really
- 8:41Speaker 2: today and tomorrow, but I do think the concern starts
- 8:44Speaker 2: becoming more significant two or three weeks from now if
- 8:47Speaker 2: the present trends continue.
- 8:50Speaker 1: And is that because people... have it but don't know
- 8:53Speaker 1: that they have it? Is that why those numbers are
- 8:55Speaker 1: going to spike like that?
- 8:56Speaker 2: I think it's a combination of everything. Clearly, there are
- 9:00Speaker 2: people that are infected. They are what we would call subclinical.
- 9:05Speaker 2: They don't have any symptoms, no signs, no symptoms. But
- 9:08Speaker 2: over the next few days or week, they may become symptomatic.
- 9:13Speaker 2: As we've talked about earlier, this virus is highly, highly contagious.
- 9:18Speaker 2: And even casual contact with somebody who's infected can result
- 9:22Speaker 2: in a new infection to the person nearby. And I
- 9:26Speaker 2: think one of the concerns we've always had about this
- 9:28Speaker 2: virus is how is it spread? And we've talked about
- 9:32Speaker 2: the idea that, sure, if somebody sneezes in your face
- 9:35Speaker 2: and coughs in your face, you have a good likelihood
- 9:38Speaker 2: of becoming infected. But it's also spread by other ways
- 9:41Speaker 2: as well. We've talked about surfaces or there is a
- 9:46Speaker 2: virus that can be found several hours later and actually
- 9:51Speaker 2: several days later, depending on what service we're talking about.
- 9:54Speaker 2: And then I think a very, very big concern, especially
- 9:56Speaker 2: to healthcare workers, is the concept of the virus being aerosolized.
- 10:02Speaker 2: You go into a room where a patient with COVID-19
- 10:06Speaker 2: has been being taken care of, that patient's been in
- 10:10Speaker 2: that room for several hours or days, and they've been coughing,
- 10:14Speaker 2: and they've been receiving breathing treatments. When that patient leaves
- 10:18Speaker 2: that room, that virus is still present in the air
- 10:21Speaker 2: in that room. The virus is attached to particles that
- 10:25Speaker 2: people cough and breathe out, and some of the heavier
- 10:29Speaker 2: particles will settle faster. The lighter particles may float away,
- 10:33Speaker 2: but there's a middle ground where some of these viral-infected
- 10:37Speaker 2: particles that we all produce, they kind of float in
- 10:39Speaker 2: the air for several hours. And one of the big
- 10:42Speaker 2: concerns is walking into a room that's been– occupied by
- 10:48Speaker 2: a corona patient and not knowing it, and then you
- 10:51Speaker 2: start breathing in these particles, you're probably going to certainly
- 10:55Speaker 2: have a significant risk of coming down with the illness.
- 10:59Speaker 1: Let's talk about some of the vaccine production, also some
- 11:03Speaker 1: of the therapies that are out there. What has been
- 11:07Speaker 1: looking to be hopeful? And if you had a patient
- 11:11Speaker 1: who had the coronavirus, would you then who is actually
- 11:16Speaker 1: more serious, would you then prescribe some of these therapies
- 11:21Speaker 1: and have you?
- 11:21Speaker 2: Yeah, well, look, I mean, bottom line, the gold standard,
- 11:27Speaker 2: the gold treatment here would be a vaccine because a
- 11:31Speaker 2: vaccine sort of prevents the illness so you don't have
- 11:33Speaker 2: to worry about treatment. I think we're a long, long
- 11:37Speaker 2: time away from getting a FDA licensed vaccine for this virus.
- 11:43Speaker 2: I think we're a very long time away from that,
- 11:46Speaker 2: at least a year.
- 11:46Speaker 1: But very long means what, a year, a year and
- 11:48Speaker 1: a half.
- 11:49Speaker 2: Five months? I would say at least 12 to 18
- 11:52Speaker 2: months because the products have to be developed, which they are,
- 11:56Speaker 2: but then you have to run the clinical trials. So
- 11:58Speaker 2: you have to inoculate the group of individuals that are
- 12:03Speaker 2: going to be under study, but then you also have
- 12:06Speaker 2: to observe the control group, the people that don't get vaccinated,
- 12:10Speaker 2: and you have to observe them for a period of time.
- 12:12Speaker 2: It's not like you can observe them for three days
- 12:15Speaker 2: and come up with an answer. You have to observe
- 12:17Speaker 2: them over a significant period of time. I'm sure it's months.
- 12:21Speaker 2: And then you look for the difference between, hey, how
- 12:24Speaker 2: many people in the control group got infected versus how
- 12:27Speaker 2: many people in the treatment vaccinated group got infected. And
- 12:32Speaker 2: then you have to look at the difference and see
- 12:35Speaker 2: if it's significant. Is it meaningful? So all this takes
- 12:39Speaker 2: time between the actual development of the product, and then
- 12:43Speaker 2: rolling it out and having people get vaccinated, and then
- 12:46Speaker 2: observing them over a period of time, and then collecting
- 12:49Speaker 2: the data, and then coming up with an opinion. It
- 12:53Speaker 2: all takes a lot of time. And all I can
- 12:55Speaker 2: tell you is look how far into the HIV AIDS
- 12:58Speaker 2: epidemic we are. There's no recognized AIDS vaccine that is
- 13:03Speaker 2: preventing people from coming down with that viral illness. So
- 13:06Speaker 2: it's more complicated than I think the media and you know,
- 13:12Speaker 2: general our politicians would like to present. It's a much
- 13:15Speaker 2: more complicated problem. And I think we're probably at a
- 13:19Speaker 2: bare minimum 12 to 18 months beyond a recognized FDA
- 13:24Speaker 2: approved vaccine.
- 13:26Speaker 1: So then let's talk about some of the therapies that
- 13:28Speaker 1: have been used that some are saying have been successful.
- 13:31Speaker 1: Others are saying, no, they haven't. There's no proven data.
- 13:34Speaker 1: It's very difficult to know what to believe. What would
- 13:37Speaker 1: you like to tell us about those therapies that you
- 13:41Speaker 1: believe to have been successful in some patients?
- 13:45Speaker 2: Well, I can tell you with certainty there is no
- 13:48Speaker 2: FDA-recognized treatment for the COVID-19 virus right now. But there
- 13:55Speaker 2: are certain products that are out there right now that
- 13:58Speaker 2: people are using. And clearly, I'm sure everybody has heard
- 14:02Speaker 2: about hydroxychloroquine, as a potential treatment, either alone or in
- 14:09Speaker 2: combination with a common antibiotic called azithromycin. There is some
- 14:14Speaker 2: good preliminary data coming out of France where that combination,
- 14:18Speaker 2: hydroxychloroquine and azithromycin, showed a benefit as compared to those
- 14:25Speaker 2: patients that were not treated with that regimen. Clearly, we
- 14:29Speaker 2: have a drug called remdesivir which is being currently explored
- 14:36Speaker 2: in clinical trials at several of the hospitals that I
- 14:38Speaker 2: go to. So right now we're in the process of
- 14:42Speaker 2: accruing patients to collect data. Just like we talked about,
- 14:45Speaker 2: you need to look at the number of patients that
- 14:47Speaker 2: get vaccinated and compare them to the patients that didn't
- 14:51Speaker 2: get vaccinated. Same thing with the remdesivir. You have to
- 14:54Speaker 2: treat some people, you don't treat others, and you see
- 14:57Speaker 2: if there's a difference in survival and outcome. But remdesivir
- 15:02Speaker 2: is an active trial. I wouldn't let anybody that I'm
- 15:06Speaker 2: taking care of, I wouldn't let anybody die without at
- 15:10Speaker 2: least trying hydroxychloroquine with azithromycin. And then there's a whole
- 15:15Speaker 2: other class of drug, what are called interleukin-6 inhibitors. When
- 15:20Speaker 2: people start coming down with this virus, and we talked
- 15:23Speaker 2: about that viral load, and that viral load, instead of
- 15:26Speaker 2: coming down, which correlates to improvement and resolving illness, when
- 15:32Speaker 2: that viral load stays elevated and people are continuing to
- 15:34Speaker 2: get sicker and sicker, you get what's called a cytokine storm,
- 15:40Speaker 2: which just means your immune system starts becoming extremely active,
- 15:44Speaker 2: becomes very, very aggressive, and then your immune system, instead
- 15:48Speaker 2: of protecting yourself, starts becoming an enemy of your body,
- 15:52Speaker 2: and it starts attacking your lung tissue, and that's why
- 15:54Speaker 2: people start developing that condition called ARDS. So there is
- 15:58Speaker 2: a new product that is in trial right now to
- 16:01Speaker 2: help block interleukin-6, which hopefully can somehow modify or lessen
- 16:08Speaker 2: this cytokine storm that's been described.
- 16:12Speaker 1: And what is that? What is that new product?
- 16:15Speaker 2: Well, the name is called tosulizumab. T-O-C-I-L-I-Z-U-M-A-B. And it's a
- 16:24Speaker 2: monoclonal antibody. It's a very high-tech type of product. And again,
- 16:29Speaker 2: it's hopefully going to throw a wrench into this whole
- 16:34Speaker 2: acute inflammatory process of which interleukin-6 is a big part of.
- 16:38Speaker 2: So if you could maybe stop this inflammatory response from
- 16:42Speaker 2: from going forward and being more and more active, you
- 16:45Speaker 2: could hopefully decrease the development of ARDS and all these
- 16:49Speaker 2: other inflammatory based illnesses.
- 16:52Speaker 1: And this sounds hopeful to me at the very least.
- 16:54Speaker 1: I mean, between this, I mean, you're all working around
- 16:57Speaker 1: the clock to try and find something to give hope,
- 17:00Speaker 1: to give, uh, you know, some science behind, um, this,
- 17:04Speaker 1: this awful disease that we've all been, um, sort of
- 17:09Speaker 1: came onto our doorstep just a few months ago. What's
- 17:13Speaker 1: it like for you, a typical day in the life
- 17:15Speaker 1: of Dr. Winters? I mean, you said you're not, you
- 17:18Speaker 1: haven't been seeing a lot of patients with COVID or
- 17:20Speaker 1: you have?
- 17:21Speaker 2: Well, I'm different. You know, I'm a little bit older
- 17:26Speaker 2: and I've been in Santa Monica for 28, going on
- 17:31Speaker 2: 29 years. And my practice has been sort of beginning
- 17:36Speaker 2: maybe a gentle retirement type of program. So I see
- 17:42Speaker 2: lots of patience, but I'm not on the front line
- 17:46Speaker 2: that I probably would have been five and ten years ago.
- 17:49Speaker 2: But I can tell you that you look at the
- 17:52Speaker 2: news reports of our colleagues back on the East Coast,
- 17:55Speaker 2: and it's an entirely different existence. So I've got a
- 17:59Speaker 2: very different experience going than what's really happening in many
- 18:03Speaker 2: parts of our country. our major cities, especially, you know,
- 18:07Speaker 2: New York City.
- 18:08Speaker 1: Yeah, well, you're clearly, you're out there, though, and you
- 18:11Speaker 1: know what's going on. So I really do appreciate it.
- 18:13Speaker 1: Any parting words that you'd like to say to us?
- 18:15Speaker 1: I feel that there's hope because I feel like science
- 18:17Speaker 1: is working on therapies to help us. I think I
- 18:21Speaker 1: know that they're working around the clock for the vaccine. Although,
- 18:24Speaker 1: to your point, I don't think we're going to see
- 18:26Speaker 1: anything at least for a year. And reports out there
- 18:30Speaker 1: are all over the place. Ah, they found the vaccine.
- 18:33Speaker 1: It's like, come on, it's not possible. They have to
- 18:35Speaker 1: do the trials or this particular therapy absolutely without question works.
- 18:40Speaker 1: I think, boy, there are so many different irresponsible reports
- 18:43Speaker 1: out there. So that's why I know that you're very
- 18:45Speaker 1: careful with the information that you put out there. Any
- 18:49Speaker 1: parting words that you'd like to say to people?
- 18:51Speaker 2: Yeah, no, I think that I have every confidence that
- 18:54Speaker 2: we will see this viral infection reach a sort of
- 19:00Speaker 2: a crescendo. we'll get a handle on it. I'm confident
- 19:04Speaker 2: the numbers will eventually start going down. And my last
- 19:09Speaker 2: point would be, eventually, I think if a vaccine doesn't
- 19:12Speaker 2: come around in real time, we will ultimately have something
- 19:15Speaker 2: called herd immunity, where when a significant number of people
- 19:19Speaker 2: in the country have been exposed and recovered, there'll be
- 19:24Speaker 2: such a large group of people that have been infected
- 19:26Speaker 2: and they have protective antibody that And it'll make it
- 19:29Speaker 2: far less likely that they'll be able to spread it
- 19:31Speaker 2: through the people that haven't been infected yet, because the
- 19:35Speaker 2: numbers will be so great of the number that have
- 19:37Speaker 2: been infected. There's so few people left now that haven't
- 19:41Speaker 2: been infected that you don't have these huge numbers that
- 19:44Speaker 2: we're currently seeing now. So ultimately, if a vaccine doesn't
- 19:48Speaker 2: come around and months or 18 months, it's clearly the
- 19:53Speaker 2: virus isn't going anywhere. I think it will eventually infect
- 19:57Speaker 2: a very significant percentage of the American population, if not
- 20:01Speaker 2: the world's population, because it's so contagious. Eventually, I think
- 20:05Speaker 2: herd immunity, and I don't want to be overly cavalier,
- 20:09Speaker 2: but You get infected and you don't survive, then it's over.
- 20:16Speaker 2: Then you can't obviously transmit an illness if you're dead.
- 20:21Speaker 2: You do get infected and you survive. You now have
- 20:24Speaker 2: protective antibody. Hopefully you won't get reinfected again. Eventually that
- 20:29Speaker 2: will go through the population of the country, if not
- 20:32Speaker 2: the world, and that's the other way that we'll solve
- 20:36Speaker 2: this problem if we don't get a vaccine first.
- 20:39Speaker 1: Okay. Interesting. Very unpredictable days out there for all of us, doctor.
- 20:45Speaker 1: I appreciate you just sort of lending your expertise to
- 20:50Speaker 1: all this because there's so many questions that we all
- 20:52Speaker 1: continue to have. Again, practice the social distancing. I'm sure
- 20:58Speaker 1: that you saw what was going on even in our
- 21:00Speaker 1: own community over the weekend with the farmer's market. We
- 21:04Speaker 1: drove past that farmer's market and we saw people literally
- 21:07Speaker 1: shoulder to shoulder. I simply couldn't believe it. Come on, people.
- 21:12Speaker 2: I think there's some degree, honestly, of denial. I mean,
- 21:16Speaker 2: I think this illness is, from my standpoint, it's fascinating
- 21:21Speaker 2: because it's just not a medical problem anymore. Clearly, it's
- 21:25Speaker 2: a political issue. It's a societal issue. It's a financial issue.
- 21:31Speaker 2: I mean, I think it's taken on so many different
- 21:34Speaker 2: forms here. And I think, at some degree, people... live
- 21:37Speaker 2: in their own world of denial. And when you have
- 21:40Speaker 2: so much press, you know, both from the federal level
- 21:44Speaker 2: and the state level, trying to encourage people to stay home,
- 21:48Speaker 2: stay away from large groups of people. I think the
- 21:51Speaker 2: magic number is 10. You know, eventually there will probably
- 21:55Speaker 2: be some recommendations to start wearing a mask when you're
- 21:57Speaker 2: out in public. And there's a lot of information out
- 21:59Speaker 2: there to tell people stop going to parties or stop
- 22:03Speaker 2: going to farmers markets, standing shoulder to shoulder with other
- 22:06Speaker 2: people I think if we can distance ourselves from each
- 22:10Speaker 2: other for a number of weeks, we could probably slow
- 22:14Speaker 2: this inevitable infection down considerably. I think, again, we're all
- 22:19Speaker 2: probably going to have a really significant chance of becoming
- 22:22Speaker 2: infected over the long term if there is no vaccine.
- 22:27Speaker 2: But it'd be good to, as they say, flatten the
- 22:31Speaker 2: curve instead of having this very steep rise in the
- 22:34Speaker 2: number of cases where they double every two or three days.
- 22:37Speaker 2: If you can draw that out, and maybe it doubles
- 22:40Speaker 2: every seven days, every two weeks, because there's fewer and
- 22:44Speaker 2: fewer people being, you know, acutely infected. Draw it out.
- 22:48Speaker 2: We can handle it. We can handle it in the hospital.
- 22:50Speaker 2: We can handle it as physicians and nurses. But I
- 22:54Speaker 2: have to tell you, I think there's denial going on.
- 22:58Speaker 1: Before I let you go, what about lots of vitamin
- 23:01Speaker 1: C and zinc? I've been reading about that. People are
- 23:04Speaker 1: running out now and getting vitamin C, and they're taking
- 23:06Speaker 1: their zinc lozenges. I mean, I guess it couldn't hurt, right?
- 23:11Speaker 2: Yeah, I don't think it's going to hurt. I think
- 23:13Speaker 2: if you take too much vitamin C, you tend to
- 23:17Speaker 2: lose it in your urine. It's what we call a
- 23:19Speaker 2: water-soluble vitamin. But there's other studies where they were looking
- 23:24Speaker 2: at hydroxychloroquine with the combination of zinc and Again, very
- 23:29Speaker 2: speculative whether it's going to be useful or not. You know,
- 23:32Speaker 2: there's just lots of different strategies. And I think vitamins
- 23:37Speaker 2: and a healthy diet are always good advice. I'm not
- 23:40Speaker 2: sure it's going to cure me, but I don't think
- 23:42Speaker 2: it's going to hurt me. Right.
- 23:44Speaker 1: People will hear the word zinc or vitamin C. That's
- 23:46Speaker 1: all they need to hear. And there's a run to
- 23:48Speaker 1: the store to go get it. I mean, people just
- 23:50Speaker 1: have to be very careful where they get their information
- 23:52Speaker 1: and listen carefully. I'm just big into the social distancing.
- 23:55Speaker 1: I feel I'm washing my hands day and night. I
- 23:57Speaker 1: feel like I'm always washing them. And I've been wrapping
- 23:59Speaker 1: a scarf around my nose and mouth. Maybe it doesn't help,
- 24:02Speaker 1: but it makes me feel better. So, you know, I'm
- 24:05Speaker 1: trying to do my little part. So there you go, doctor.
- 24:07Speaker 1: I really appreciate you coming on.
- 24:08Speaker 2: So far, so good.
- 24:10Speaker 1: Yeah, so far, so good. I appreciate you always being
- 24:12Speaker 1: there for us. So thank you, Dr. Robert Winters, infectious
- 24:16Speaker 1: disease specialist for joining us today. I'm Debra Kobet live
- 24:19Speaker 1: and everybody. You could see our show on Facebook and YouTube.
- 24:24Speaker 1: And for those of you who listen to your podcast,
- 24:26Speaker 1: you can hear us on iHeartRadio, on Apple Podcasts, on Spreaker,
- 24:31Speaker 1: on Spotify, and anywhere else that you get your podcasts,
- 24:35Speaker 1: we will be there. So again, thank you to the
- 24:37Speaker 1: doctor for taking the time and everybody else. And we'll
- 24:41Speaker 1: see you next time. Bye-bye.